Abstract
Testing for active SARS-CoV-2 infections is key to controlling the spread of the virus and preventing severe disease. A central public health challenge is defining test allocation strategies in the presence of limited resource and/or multiple competing test options. In this paper, we provide a mathematical frame-work for defining an optimal strategy for allocating viral tests. The framework accounts for imperfect test results, testing in certain high-risk patient populations, practical constraints in terms of budget and/or total number of available tests, and the goal of testing. In our proposed approach, tests can be allocated across population strata defined by symptom severity and other patient characteristics, allowing the test allocation plan to prioritize higher risk patient populations. We extend our proposed method to address the challenge of allocating two different types of tests with different cost and accuracy (for example the expensive but more accurate RT-PCR test versus the cheap but less accurate rapid antigen test), administered under budget constraints. We provide a R Shiny web application allowing users to explore test allocation strategies across a variety of pandemic scenarios. This work can serve as a useful tool for guiding public health decision-making at a community level, adapted to different stages of the pandemic. We use distribution of tests in New York City during the initial wave of the COVID-19 outbreak as a sample example. We also show how this framework can be useful to reopening of college campuses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work is supported by NSF DMS 1712933 and a pilot grant by the Michigan Institute of Data Science.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
no IRB.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.